SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society, California Division and Public Health Institute, California Cancer Registry. California Facts and Figures 2007. Oakland, Calif: American Cancer Society, Division; 2006.
  • 2
    Campleman S,Curtis R. Demographic aspects of breast cancer incidence and mortality in California, 1988–1999. In: MorrisC,KwongSL, eds. Breast Cancer in California, 2003, vol July. Sacramento, Calif: California Department of Health Services, Cancer Surveillance Section; 2004.
  • 3
    Chlebowski RT,Chen Z,Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005; 97: 439448.
  • 4
    Jatoi I,Anderson WF,Rao SR,Devesa SS. Breast cancer trends among black and white women in the United States. J Clin Oncol. 2005; 23: 78367841.
  • 5
    Shavers VL,Harlan LC,Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003; 97: 134147.
  • 6
    Jayasinghe UW,Taylor R,Boyages J. Is age at diagnosis an independent prognostic factor for survival following breast cancer? Aust N Z J Surg. 2005; 75: 762767.
  • 7
    Swanson GM,Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr. 1994; 16: 6977.
  • 8
    Hartley MC,McKinley BP,Rogers EA, et al. Differential expression of prognostic factors and effect on survival in young (≤40) breast cancer patients: a case-control study. Am Surg. 2006; 72: 11891194; discussion 1194–1195.
  • 9
    Jmor S,Al-Sayer H,Heys SD,Payne S,Miller I,Ah-See A, et al. Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinburgh. 2002; 47: 693699.
  • 10
    Frost F,Tollestrup K,Hunt WC,Gilliland F,Key CR,Urbina CE. Breast cancer survival among New Mexico Hispanic, American Indian, and non-Hispanic white women (1973–1992). Cancer Epidemiol Biomarkers Prev. 1996; 5: 861866.
  • 11
    Campbell JB. Breast cancer-race, ethnicity, and survival: a literature review. Breast Cancer Res Treat. 2002; 74: 187192.
  • 12
    Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003; 22: 5565.
  • 13
    Field TS,Buist DS,Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005; 35: 8895.
  • 14
    Esteva FJ,Sahin AA,Cristofanilli M,Arun B,Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002; 12: 319328.
  • 15
    Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat. 2002; 73: 4559.
  • 16
    Ademuyiwa FO,Olopade OI. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev. 2003; 22: 4753.
  • 17
    Huang HJ,Neven P,Drijkoningen M, et al. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat. 2005; 91: 8187.
  • 18
    Hlupic L,Jakic-Razumovic J,Bozikov J,Coric M,Belev B,Vrbanec D. Prognostic value of different factors in breast carcinoma. Tumori. 2004; 90: 112119.
  • 19
    Wu Y,Khan H,Chillar R,Vadgama JV. Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer. Int J Oncol. 1999; 14: 10211037.
  • 20
    Tandon AK,Clark GM,Chamness GC,Ullrich A,McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989; 7: 11201128.
  • 21
    Kroger N,Milde-Langosch K,Riethdorf S, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006; 12: 159168.
  • 22
    Goldhirsch A,Glick JH,Gelber RD,Coates AS,Thurlimann B,Senn HJ. Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol. 2005; 16: 15691583.
  • 23
    Menard S,Fortis S,Castiglioni F,Agresti R,Balsari A. HER2 as a prognostic factor in breast cancer. Oncology. 2001; 61( suppl 2): 6772.
  • 24
    Luftner D,Jung A,Schmid P, et al. Up-regulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. Breast Cancer Res Treat. 2003; 80: 245255.
  • 25
    Dowsett M,Cooke T,Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer. 2000; 36: 170176.
  • 26
    Jumppanen M,Gruvberger-Saal S,Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers [electronic resource]. Breast Cancer Res. 2007; 9: R16.
  • 27
    Early Breast Cancer Trialist's Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 16871717.
  • 28
    Grann VR,Troxel AB,Zojwalla NJ,Jacobson JS,Hershman D,Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005; 103: 22412251.
  • 29
    Slamon DJ,Leyland-Jones B,Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783792.
  • 30
    Vogel CL,Cobleigh MA,Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719726.
  • 31
    Perou CM,Sorlie T,Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747752.
  • 32
    Sorlie T,Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 1086910874.
  • 33
    Carey LA,Perou CM,Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 24922502.
  • 34
    Collins LC,Schnitt SJ,Colditz GA, et al. Risk factors for luminal, HER2, and basal-like breast cancer subtypes: results from a tissue microarray-based analysis of invasive breast cancers from women enrolled in the Nurses' Health Study [Abstract 5041]. Breast Cancer Res Treat. 2006; 100( suppl 1): S275.
  • 35
    Rakha EA,El-Rehim DA,Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006; 42: 31493156.
  • 36
    Lakhani SR,Reis-Filho JS,Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005; 11: 51755180.
  • 37
    Mountain JL,Risch N. Assessing genetic contributions to phenotypic differences among ‘racial’ and ‘ethnic’ groups. Nat Genet. 2004; 36(11 suppl ): S48S53.
  • 38
    Lund MB,Eley JW,Brawley OW,Liff JM,Coates RJ,Porter PL. Racial differences in triple negative breast tumors among women in Atlanta [abstract]. Proc Am Assoc Cancer Res. 2006; 47; LB-4.
  • 39
    Bauer KR,Brown M,Cress RD,Parise CA,Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007; 109: 17211128.
  • 40
    Caggiano V,Brown M,Bauer KR,Tsodikov A,Parise C. Incidence, risk factors, and survival among triple negative phenotypic (estrogen receptor, progesterone receptor, and HER2 negative) breast cancers in California, 1999–2003 [Abstract 6057]. Breast Cancer Res Treat. 2006; 100( suppl 1): S275.
  • 41
    California Department of Health Services, Cancer Surveillance Section. Cancer Reporting in California: Standards for Automated Reporting. California cancer reporting system standards, vol II. Sacramento, Calif: California Department of Health Services, Cancer Surveillance Section; 2006.
  • 42
    Percy C,Fritz A,Jack A, et al. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 43
    Bauer KR,Brown M,Creech C,Schlag NC,Caggiano V. Data quality assessment of HER2 in the Sacramento Region of the California Cancer Registry. J Registry Manage. 2007; 34: 47.
  • 44
    Fritz A.Recording Tumor Markers in Collaborative Staging System Site-Specific Factors, vol 2006. 2005. Available at URL: http://ccrcal.org/PDF/ATTACH-TumormMarkers-6-06.pdf. Accessed December 18, 2007.
  • 45
    DAKO. HERCEPTest® Information Web site. Summary of Procedure. Available at URL: www.dakousa.com/prod downloadpackageinsert.pdf?objectid=114969002. Accessed December 18, 2007.
  • 46
    Vysis, Inc. PathVysion®: HER-2 DNA Probe Kit [package insert]. Downers Grove, Ill: Vysis, Inc.; 2002.
  • 47
    Stewart SL,Swallen KC,Glaser SL,Horn-Ross PL,West DW. Comparison of methods for classifying Hispanic ethnicity in a population-based cancer registry. Am J Epidemiol. 1999; 149: 10631071.
  • 48
    Yost K,Perkins C,Cohen R,Morris C,Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001; 12: 703711.
  • 49
    GreeneFL,PageDL,FlemingID, et al., eds. AJCC Cancer Staging Manual,6th ed. New York, NY: Springer-Verlag; 2002.
  • 50
    FritzA,RiesL, eds. SEER Extent of Disease 1998, Codes and Coding Instructions,3rd ed. Bethesda, Md: National Cancer Institute, National Institutes of Health; 1998.
  • 51
    Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative Staging Manual and Coding Instructions, version 01.03.00. Jointly published: Chicago, Ill; American Joint Committee on Cancer;Bethesda, Md,U.S. Department of Health and Human Services; 2004.
  • 52
    Seiffert JE, National Cancer Institute (US). SEER Program. Comparative Staging Guide for Cancer. Bethesda, Md: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1993.
  • 53
    Fleiss JL,Levin BA,Paik MC. Statistical Methods for Rates and Proportions, 3rd ed. Hoboken, NJ: Wiley-Interscience; 2003.
  • 54
    Broet P,De Rycke Y,Tubert-Bitter P,Lellouch J,Asselain B,Moreau T. A semiparametric approach for the 2-sample comparison of survival times with long-term survivors. Biometrics. 2001; 57: 844852.
  • 55
    Tsodikov A. A proportional hazards model taking account of long-term survivors. Biometrics. 1998; 54: 15081516.
  • 56
    Tsodikov AD,Ibrahim JG,Yakovlev AJ. Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc. 2003; 98: 10631078.
  • 57
    Carter CL,Allen C,Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181187.
  • 58
    Fisher B,Slack NH,Bross ID. Cancer of the breast: size of neoplasm and prognosis. Cancer. 1969; 24: 10711080.
  • 59
    Koscielny S,Tubiana M,Le MG, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer. 1984; 49: 709715.
  • 60
    Cunningham JE,Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat. 2004; 88: 161176.
  • 61
    Menard S,Casalini P,Campiglio M,Pupa S,Agresti R,Tagliabue E. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001; 12( suppl 1): S15S19.
  • 62
    Sorlie T,Tibshirani R,Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 84188423.
  • 63
    Sotiriou C,Neo SY,McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003; 100: 1039310398.
  • 64
    Chu KC,Lamar CA,Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003; 97: 28532860.
  • 65
    Newman LA. Breast cancer in African-American women. Oncologist. 2005; 10: 114.
  • 66
    Ries L,Eisner M,Kosary M. SEER Cancer Statistics Review, 1975–2000. Bethesda, Md: National Cancer Institute; 2003.
  • 67
    Woods LM,Rachet B,Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006; 17: 519.
  • 68
    Elledge RM,Clark GM,Chamness GC,Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994; 86: 705712.
  • 69
    Boyer-Chammard A,Taylor TH,Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev. 1999; 23: 463473.
  • 70
    El-Tamer MB,Wait RB. Age at presentation of African-American and Caucasian breast cancer patients. J Am Coll Surg. 1999; 188: 237240.
  • 71
    Aziz H,Hussain F,Sohn C, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 1999; 22: 436440.
  • 72
    Boyle T,McPadden E. Breast cancer presents at an earlier age in Mexican American women. Breast J. 2004; 10: 462464.
  • 73
    Colon E,Reyes JS,Gonzalez Keelan C,Climent-Peris C. Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico. P R Health Sci J. 2002; 21: 299303.
  • 74
    Hsu JL,Glaser SL,West DW. Racial/ethnic differences in breast cancer survival among San Francisco Bay Area women. J Natl Cancer Inst. 1997; 89: 13111312.
  • 75
    Ayanian JZ,Kohler BA,Abe T,Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993; 329: 326331.
  • 76
    Breen N,Wesley MN,Merrill RM,Johnson K. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis. 1999; 9: 111125.
  • 77
    Bradley CJ,Given CW,Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002; 94: 490496.
  • 78
    Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002; 94: 471473.
  • 79
    O'Malley CD,Le GM,Glaser SL,Shema SJ,West DW. Socioeconomic status and breast carcinoma survival in 4 racial/ethnic groups: a population-based study. Cancer. 2003; 97: 13031311.
  • 80
    Yood MU,Johnson CC,Blount A, et al. Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst. 1999; 91: 14871491.
  • 81
    Franzini L,Williams AF,Franklin J,Singletary SE,Theriault RL. Effects of race and socioeconomic status on survival of 1,332 black, Hispanic, and white women with breast cancer. Ann Surg Oncol. 1997; 4: 111118.
  • 82
    Wolff AC,Hammond ME,Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118145.